abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
1331P: Tetanus & Diphtheria Toxoid IgG Antibodies, Pre/Post Vaccination Print View
Preimmunization Date Drawn      
Postimmunization Date Drawn      
Diphtheria Toxoid Antibodies Pre EIA  > .099  IU/mL 
Diphtheria Toxoid Antibodies Post EIA  > .099  IU/mL 
Diphtheria Toxoid Post/Pre Ratio CALC  > 4.0   
Tetanus Toxoid Antibodies Pre EIA  > .150  IU/mL 
Tetanus Toxoid Antibodies Post EIA  > .150  IU/mL 
Tetanus Toxoid Antibodies Post/Pre Ratio CALC  > 4.0   

PRIMARY
1 Serum Acute Pre 2 (1) mL   Frozen - 2 Month(s)/Room Temperature - 7 Day(s)/Refrigerated - 14 Day(s) Please label tubes pre and post./// 
2 Serum Convalescent Post 2 (1) mL   Frozen - 2 Month(s)/Refrigerated - 14 Day(s)/Room Temperature - 7 Day(s)  
ALTERNATE

Used to evaluate Diphtheria and Tetanus immunization efficacy. A postvaccination to prevaccination ratio of greater than 4 is a good responder.

Serum should be obtained 3-4 weeks after primary immunization or 2-3
weeks after booster if clinically indicated and tested simultaneously
with the pre-vaccination sample. Pre- and post-vaccination sera
must be sent together. Please label the tubes "pre" and "post"
so that the sera can be assayed simultaneously.


Rejection Criteria:
Grossly hemolyzed, grossly lipemic, or grossly icteric specimens.
Setup Schedule
Tuesday, Thursday, Saturday

Reported (Analytical Time)
Same day

CPT Codes
86648x2, 86774x2

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Diphtheria Toxoid Abs: This test(s) was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Specialty Laboratories. This test should not be used for diagnosis without confirmation by other medically established means. Tetanus Toxoid Abs: This test(s) was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, Valencia, CA. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database